The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a useful extension to its diabetes treatments. While the stock rose 2.85% to $1,183.76, this new insulin is unlikely to significantly change the company's growth trajectory, which is currently driven by volume growth in other drugs like Mounjaro. The key unknown remains the pricing and launch details of Onswik. Investors are watching Lilly's pipeline, including the upcoming weight-loss drug Retatrutide, for future growth potential.
Eli Lilly's stock price on Pluang stands at USD 1,183.72 with a minimal 1-day change of -0.01% as of Sep 28, 2026 02:02 WIB. The company's market cap is $1.05 trillion, reflecting its significant presence in the health sector. This stable trading environment on Pluang coincides with the FDA approval of its once-weekly insulin, Onswik, which adds to its portfolio but is not expected to drastically alter its growth trajectory.
The FDA has approved Olumiant (baricitinib), a once-daily pill, for treating severe alopecia areata (AA) in pediatric patients aged 12 and older. This approval is based on positive results from the BRAVE-AA-PEDS Phase 3 study, showing significant sca...
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
The US FDA has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, offering a new alternative to daily insulin injections. Onswik, used alongside diet and exercise, can reduce injection frequency by over 300 times...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
